Targeting Cooperation of Chronic Inflammation with Epigenetic Reprogramming Triggers a Synthetic Lethality in Glioblastoma Multiforme

Kefeng Lin

Dalian Medical University

Wenli Gao

Dalian Medical University

Ning Chen

Dalian Medical University

Han Wang

Dalian Medical University

Ran Wang

Dalian Medical University

Shuyao Yang

Dalian Medical University

Fang Xie

Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Second Hospital of Dalian Medical University

Jiaqi Meng

Dalian Medical University

Eric W.-F. Lam

Sun Yat-sen University Cancer Center

Chao Ma

Dalian Medical University

Suyi Li

Dalian Medical University

Ning Kang

Dalian Medical University

Yuchao Hao

Dalian Medical University

Zheng Wu

Dalian Medical University

Qi Ge

Dalian Medical University

Lili Guo

Dalian Medical University

Wei Cheng

Dalian Medical University

Puxiang Chen

Central South University

Hongjin Wu

Shanghai University of Traditional Chinese Medicine

Jinsong Yan

Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Second Hospital of Dalian Medical University

Di Jin

Dalian Medical University

Bilian Jin (✉ bjinmcbg@outlook.com)

Dalian Medical University

Research Article

Keywords: GBM, Inflammation, Epigenetic reprogramming, NF-κB, EZH2

Posted Date: March 2nd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1394307/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Without an effective strategy for targeted therapy, glioblastoma multiforme (GBM) is still incurable, with a median survival of only 15 months. Both chronic inflammation and epigenetic reprogramming are hallmarks of cancer. However, the mechanisms and consequences of their cooperation in GBM remain unknown.

Methods

Western blotting was carried out to detect levels of various histone modifications affected by NF- κ B signalling. Then, RNA-seq was used to screen genes encoding methyltransferases and demethylases of histone. Dual-luciferase reporter gene and ChIP assays were performed to determine whether NF- κ B activates the transcription of EZH2. Subsequently, ChIP-seq and RT-qPCR were performed to explore the variety of H3K27me3 distribution. Expression levels of p65 and EZH2 in glioma samples were evaluated by IHC, and tumorigenicity assays (*in vitro* and *in vivo*) were performed to demonstrate the effects of combining NF- κ Bi and EZH2i on GBM progression.

Results

We discovered that chronic inflammation governs H3K27me3 reprogramming in GBM through the canonical NF- κ B pathway to target EZH2. Being a crucial mediator of chronic inflammation, the canonical NF- κ B signalling specifically directs the expression and redistribution of H3K27me3 but not H3K4me3, H3K9me3 and H3K36me3. Then, we identified EZH2 as a key methyltransferase to control inflammation-triggered epigenetic reprogramming in gliomagenesis. Mechanistically, NF- κ B selectively drives the expression of EZH2 by activating its transcription, consequently resulting in a global change of H3K27me3 expression and distribution. Furthermore, we find that co-activation of NF- κ B and EZH2 confers the poorest clinical outcome, and that the risk for GBM can be accurately molecularly stratified by NF- κ B and EZH2. It is notable that NF- κ B can potentially cooperate with EZH2 in more than one way, and most importantly, we demonstrated a synthetic lethality of cancer cells induced by combinatory inhibition of NF- κ B and EZH2, which both are frequently over-activated in GBM.

Conclusions

We uncover a functional cooperation between chronic inflammation and epigenetic reprogramming in GBM. Thus, combined targeting of NF- κ B and EZH2 by inhibitors can be a potent strategy for the effective treatment of this fatal disease.

Introduction

Glioblastoma multiforme (GBM), the most aggressive tumour in the central nervous system, is still incurable with an intermediate survival of only 15 months[1, 2]. In past decades, great efforts have been made to search for appropriate targets for therapy. So far, however, no effective strategy of targeted therapy has been developed in the clinic.

Previous researches have suggested that chronic inflammation is a cardinal feature of GBM biology[3, 4]. The blood-brain barrier is destroyed by GBM, causing chronic neuroinflammation[5, 6]. The inflammatory microenvironment is an essential component of the vast majority of tumours to drive their malignant progression[7, 8]. In consequence, the mechanisms connecting inflammation to tumorigenesis have been a primary focus of cancer research[7, 9]. NF- κ B is a key transcription factor linking chronic inflammation and cancer[10, 11]. Solid and direct genetic evidence showed that the NF- κ B signalling is an essential mediator of tumour promotion[12, 13]. Similar to other carcinomas, GBM displays high constitutive NF κ B activity, and various central tumorigenic signaling pathways of GBM converge on NF κ B[14, 15].

Epigenetic modifications are central to cancer[16, 17]. Histone lysine methylation is one of the best-characterized histone modifications[18, 19]. The function of lysine methylation depends on its site of residue and the degree of methylation (mono, di or trimethylation) in the tail structure[20]. The most widely researched histone methylation loci comprise of H3K4, H3K9, H3K27, and H3K36, etc[18, 21]. H3K27me₃ is recognized as a vital epigenetic modification during differentiation and proliferation[22], and dysregulation of which was constantly observed in many kinds of tumours, including GBM[23, 24].

Both chronic inflammation and epigenetic reprogramming are hallmarks of cancer[25]. However, whether there exists a functional cooperation between them in GBM remains unclear. Here, we discover that the NF- κ B activation dictates the methylation of H3K27, and we identify EZH2 as an essential methyltransferase to control the reprogramming of histone modification. Significantly, co-activation of NF- κ B and EZH2 confers the poorest clinic outcome and GBM can be molecularly stratified by NF- κ B and EZH2. Most importantly, cancer cells are induced to a synthetic lethality by combinatory inhibition of NF- κ B and EZH2. Both NF- κ B and EZH2 have long been regarded as crucial targets for cancer treatment. However, targeting each of them alone has never been successful in clinic except that several inhibitors are guaranteed in safety and availability. Combined targeting of them by pharmaceutical interventions uncovers a novel potent strategy for GBM patients.

Materials And Methods

Mice

Nud mice were reared in SPF. On the first day, we implanted 5×10^6 LN229 cells in 200 μ l PBS into mice subcutaneously. The mice were then randomly apart into four groups. Tumour volume was measured per 4 days. We intraperitoneally injected CAPE (Selleck, S7414, 10mg/kg in DMSO) or orally administered

EPZ-6438 (Selleck, S7128, 100mg/kg in corn oil) to mice for 28 consecutive days. Twenty-eight days after injection, we euthanized the mice and gauged the tumour weight. The tumours were examined by H&E or IHC staining following the protocol in the kit. The animal assays were conducted in obedience to the recommendations from the animal ethics committee (Dalian Medical University) and conformed to local regulations.

Tissue microarrays

Tissue microarray slides containing 180 GBM were handled as follows: The slides were deparaffinized in xylene by heating for 1 hour at 60°C and subsequent rehydration with ethanol. Antigen retrieval was performed in a chamber containing citrate buffer (pH 6.0) for 20 min maintaining at a sub-boiling temperature. Endogenous peroxidase activity was blocked by treating the slides in methanol with 3% hydrogen peroxide for 10 min. Samples were blocked with 10% goat serum for one h each at room temperature. 200µl primary antibody was added to each slide and incubated overnight at 4°C. The second antibody with Streptavidin/Peroxidase was added for immunochemistry staining assay. For each tissue sample, protein expression was scored according to the staining color: negative staining (no yellow); low staining (light yellow); moderate or high staining (yellow-brown or brown). With prior written consent from patients, all the tissue samples had been obtained before anti-cancer treatment. All of the methods in this study were in accordance with the approved guidelines, and all of the experimental protocols were approved by the ethics committee of Xinchao (Shanghai).

Cell Culture

293T cells were cultivated in DMEM with 1% penicillin (100 IU/ml) and streptomycin (100 mg/ml) and 10% fetal bovine serum (FBS). LN229 and U251 (GBM cell lines) were nurtured in DMEM medium supplemented with 5% or 10% FBS. All cells were bought from American Type Culture Collection (ATCC) and continuously cultured at 37°C with 5% CO₂ incubator. Cell lines were routinely confirmed by STR allele profile and validated to be free of mycoplasma via the Lonza kit (LT07-218; Lonza Biologics, Guangzhou, China).

Immunofluorescence

Five x10⁴ LN229 and U251 cells were grown on coverslips, which were cultured for one night. After fixing in 4% paraformaldehyde for 15 min, cells were washed three times and permeabilized for 15 min. Cells were blocked before incubating with a certain primary antibody in a cold room overnight. After 12 h, cells were washed three times in PBS before incubation for 1 h with a corresponding fluorescent secondary antibody, followed by incubating with Hoechst 33342 for 15 min. Immunofluorescence images were taken by Leica SP5 Confocal Microscope (Leica Microsystems, Mannheim, Germany).

Western Blot Analysis

Cells were collected and boiled for 10 min in the RIPA buffer (Sigma). 20 µg protein were resolved on SDS-PAGE gels and electro-transferred onto nitrocellulose membranes (Millipore, Merck, Shanghai, China) using a power supply (BIO-RAD, Guangzhou, China) at 250 mA for two h. Membranes were blocked by

non-fat milk. Antibodies: p65 (Cell Signalling Technology, Shanghai, China; 6956, 1:1000), p-p65 (Ser536, Cell Signalling Technology, 3033, 1:1000), EZH2 (Cell Signalling Technology, 5246, 1:1000), H3K4me3 (Cell Signalling Technology, 9751, 1:1000), H3K9me3 (Cell Signalling Technology, 13969; 1:1000), H3K36me3 (Cell Signalling Technology, 4909, 1:1000), H3K27me3 (Cell Signalling Technology, 9733, 1:1000), H3K27me2 (Cell Signalling Technology, 9728, 1:1000), H3K27me1 (Cell Signalling Technology, 84932, 1:1000), H3 (Abcam,, Hangzhou, China; Ab1791, 1:10,00), ACTB(Cell Signalling Technology, 4970, 1:1000), NFKB1(Cell Signalling Technology, 13586, 1:1000), NFKB2 (Cell Signalling Technology, 37359, 1:1000) and GAPDH (Cell Signalling Technology, 97166, 1:3000). The blots were covered with respective primary antibodies at cold room and corresponding secondary antibodies (1:3000, ThermoFisher, USA). The membranes were processed using an ECL kit (ThermoFisher, USA).

RNA extraction and qRT-PCR

The total cellular RNA in the GBM cells was isolated by TRIZOL reagent (Invitrogen). Then, cDNA was reversed from 1 µg total RNA by the RT Reagent Kit (RR037A, TAKARA, Beijing, China). The primer sequences are filed in Supplementary Table 4. Program conditions for RT-qPCR reaction are in obedience to the recommendations. For making sure authenticity, each assay was performed at least three times and normalized to the internal control, β -Actin. We used the delta CT method to calculate the gene expression levels between different groups.

Transfection

siRNA was transfected into GBM cells with lipo2000 (ThermoFisher, USA) for 48h. SgRNA was transfected into HEK293T cells along with psPAX2 (Addgene, 8454) and PMD2.G (Addgene, 12260). Viruses were harvested 48 and 72 h after transfection, which were filtered using a 0.45 µm nitrocellulose filter. Such stocks were then concentrated by ultracentrifugation or precipitation using polyethylene glycol 6000, resulting in viral titers 1×10^8 transducing units per milliliter or above by lentivirus qPCR Titration kit (TransLvTM; TransGen Biotech Co, DongShen, China) analysis. Virus infects target cells with polybrene (8 mg/ml) after spinoculation at 4500 x g for 30 min at 4°C. The next day, cells were subsequently screened with puromycin for 48 h (2–5 µg/ml, Sigma). After that, cells were transferred to 10 cm dishes and maintained for experimental purposes. The method of constructing an *EZH2*-coding plasmid that reported stable overexpression strain is the same as described above.

CRISPR-Cas9

EZH2 or p65 knockout GBM cells were generated by the CRISPR/Cas9 system from Zhang laboratory. In summary, *EZH2* or p65-specific sgRNAs were designed by the CRISPR design tool and constructed into the lentiCRISPR V2 vector (Addgene, MA, USA, 63592). Next, HEK293T cells were treated with the sgRNA, pVSVg and psPAX2. The viruses were concentrated by ultracentrifugation or precipitation using polyethylene glycol 6000. After spinoculation at 4500 x g for 30 min at 4°C, cells were infected with lentiviruses (multiplicity of infection of 5 and 8 µg/ml polybrene) harboring a target plasmid or empty vector control. Cells were subsequently screened with puromycin (2–5 µg/ml, Sigma) for two days. The final concentration was 60 cells per 10ml by limiting dilution method. Then the 96-well plates were plated

and cultured for seven days until every single cell grew into a monoclonal cell line. Cell clones with EZH2/p65 stable knockout were verified by RT-PCR and sequencing.

Cell proliferation assay

Cell proliferative ability was detected using a CCK-8 kit (Merck) according to the protocol. After treatment, $1-2 \times 10^3$ cells were cultivated for four days, and 10 μ l of the CCK-8 kit was added. Thereafter, the samples were incubated for two hours in the dark at 37°C with 5% CO₂. 450 nm OD value was detected with a microplate reader. As for the Colony formation assay, cells (500 or 1000 cells) were cultured with a complete medium for 7 to 14 days. Cells were then washed with PBS, and fixed for 30 min and stained with 0.1% crystal violet solution.

Flow cytometry

LN229 and U251 cells were counted (1×10^6 cells) and treated or not treated with VP16 for 24 h at 10 μ M for apoptosis assay. The Apoptosis Kit (BD Biosciences, Shanghai, China) was in obedience to recommendations. Cells were re-suspended in 500ul 1 x Binding. We incubate 5 μ l Annexin V for 15 min and 5 μ l propidium iodide for another 5 min on ice. About cell cycle analysis, we washed the treated cells with PBS and incubated them with 70% ethanol at -4°C overnight. Then we re-suspended the cells and stained them in 500ul of PI containing 25ug/ml RNase for 15min at RT. Finally, the cells were performed on BD C6 (BD Biosciences) and analysed using Flowjo(SRI, USA)

Transwell assay

LN229 and U251 were re-suspended in serum-free FBS DMEM. 5×10^3 or 1×10^4 cells were placed on each transwell chamber (8 μ m, BD Biosciences) and the complete medium was applied under the chambers subsequently. After two days, the upper migrated cells on the membrane surface were washed with PBS, fixed for 30 min and stained with 0.1% crystal violet solution. Cells were observed under a microscope in five random fields.

Dual-luciferase reporter gene assay

The transfected cells were subjected to luciferase assays using the Dual-luciferase Reporter Assay System (Promega, Madison, WI, USA). Promoter constructs were generated by cloning the region of the human *EZH2* promoter from - 626 to + 288 and inserting it between the EcoRI and KpnI restriction sites of the pGL4.15 vector (Promega). GBM cells were transfected with either the pGL4.15 (Promega) or *EZH2* promoter-luciferase constructs. After 24 h, the transfected cells were lysed and processed according to the Dual-luciferase Reporter Assay System protocol. The promoter reporter activities were detected by a microplate reader (Tecan, Switzerland) and normalized with Renilla luciferase activities.

RNA-seq

Control and treated samples were collected using TRIZOL reaction solution (ThermoFisher). Library preparation and RNA sequencing were completed at Novagene (Beijing, China). The statistical difference in gene expression was determined by the adjusted P-value cutoff value of 0.05 and the fold change

cutoff value of 2. To determine statistically significant enrichment, we use the GO-seq R package to perform gene ontology (GO) analysis of differentially expressed genes. The corrected P-value cutoff value is 0.05 at this time.

ChIP and ChIP-seq

Cells from two independent experiments were fixed at RT for 15 min before neutralizing by glycine. The lysates were shear to approximately 200 ~ 1000 bp fragments in sonication buffer. The chromatin solutions were precipitated 4h with certain antibodies or IgG. The Immunoprecipitation was caught by magnetic beads. After the immunocomplexes were washed 5 min for three times, the captured DNA fragments were eluted by proteinase K digestion. Multiplexed libraries were sequenced either on an Illumina NextSeq 500 or a HiSeq-2500 sequencer. Peak calling for individual IPs was performed using the call peak function from the model-based analysis of ChIP-seq 2 (MACS2) program. Peaks were re-called using the pooled IP and the corresponding pooled Input with the nonmodel option. To ensure the significant ($\log_{10}$ likelihood ratio > 3) differential peaks, the fold enrichment of (Pooled IP/Pooled Input) was calculated for each group and normalized to reads per million.

Statistical analysis

Statistical analyses were processed by Prism GraphPad. The data were presented as the mean values $\pm$ standard deviation. Each quantitative assay in this study was performed in at least independent triplicates. $P < 0.05$ means statistical difference.

Database analyses

We downloaded RNA-seq data for 325 glioma patients with clinical data from CGGA database. First of all, we divided the samples into three panels in accordance with the expression levels of *EZH2* and p65. Survival data by the Kaplan-Meier survival analysis includes life status, days of death and other variables. The relationship between *EZH2* mRNA expression and NF- κ B subunits mRNA expression was analysed using the Pearson correlation analysis.

Results

Canonical NF- κ B signalling specifically activates global methylation of H3K27 in GBM

Recent research discovered that NF- κ B, the key transcription factor linking chronic inflammation with cancer[26], displays constitutive activity in primary GBM where phosphorylated and total p65 expression is significantly upregulated [27]. To confirm that, we examined the status of NF- κ B activation in 6 pairs of GBM tumour and normal samples and five general glioma cell lines, and the results suggested that their expression is frequently upregulated in GBM (Fig. 1a, b). The LN229 cells were found to have relatively high p65 expression, while U251 was found to have comparatively low p65 expression (Fig. 1b, c). Thus, we chose LN229 and U251 for further studies.

Histone lysine methylation plays a critical role in epigenetic modification and transcription[20]. Thus, we sought to explore the impacts of NF- κ B on trimethylation of H3 on Lys4, Lys9, Lys27, and Lys36 residues. To establish a system to monitor the impact of NF- κ B activation, we examined NF- κ B-activated luciferase values in the treatment of both NF- κ B activators and inhibitors. The results showed that the NF- κ B activators LPS and TNF- α promoted and the inhibitors BAY11 and CAPE repressed NF- κ B-driven transcriptional activity dose-dependently in both LN229 and U251 cell lines (Fig. S1a, b), validating the ability of our luciferase reporter gene assay to monitor NF- κ B activity in glioma cell lines. Then we studied their effects on H3K4-, H3K9-, H3K27 and H3K36-trimethylation using Western blot analysis. The NF- κ B activators and inhibitors caused a change in the tri-methylation levels of H3K27 in both cell lines. In contrast, the tri-methylation levels of H3K4, H3K9 and H3K36 were largely unaffected (Fig. 1d and Fig. S1c). Next, we utilized siRNA and overexpression vector to deplete and increase p65 expression respectively in LN229 and U251 cells. The results are consistent with the chemical activators and inhibitors (Fig. 1e and Fig. S1d). Furthermore, the H3K27 trimethylation was downregulated in p65 knockout (p65 KO) cells but could be restored by the re-expression of p65 (Fig. 1f). To further confirm our results, we also studied the effects of NF- κ B on the methylation levels of H3K27. Our findings revealed that the NF- κ B could upregulate H3K27me1, -me2, and -me3 levels (Fig. 1g, h and Fig. S1e, f). Together, the above results showed that adjusting the activity of NF- κ B in GBM cells promotes the methylation of H3K27.

NF- κ B selectively triggers the expression of EZH2 to promote H3K27 methylation in GBM

Histone methyltransferases and demethylases regulate histone methylation widely[28]. To identify the enzymes potentially responsible for H3K27 trimethylation in GBM, we reviewed the list of H3K27 specific methyltransferases and demethylases from GO term (GO ID: 0046976, 0071558). Next, we used RNA-seq to identify the histone lysine methyltransferases and demethylases differentially expressed in LN229 cells following treatment with the potent NF- κ B inhibitor CAPE and p65 KO (Fig. 2a and Fig. S2a, b). Recognized as an H3K27 specific methyltransferase, EZH2 was found to be one of the candidates. Our results revealed that EZH2 expression was modulated upon treatment with NF- κ B activators and inhibitors (Fig. 2b and Fig. S2c).

Five members of the NF- κ B family form several homodimers or heterodimers, but the most dominant form is p50/p65 that regulates the canonical NF- κ B pathway[29]. To identify the exact NF- κ B pathway affecting the regulation of EZH2 in GBM, we used siRNAs to knockdown individual NF- κ B family members and investigated EZH2 protein expression in LN229 and U251 cells (Fig. 2c). The results suggested that the NF- κ B canonical signalling is the primary pathway to regulate EZH2 expression in GBM. In agreement, the correlation coefficient(r) between EZH2 and p65 expression is also the highest amongst NF- κ B subunits in GBM tissues from the CGGA database (Fig. S2d). Consequently, we focused our study on the p65, a major subunit of the canonical pathway involved in NF- κ B heterodimers.

p65 depletion or overexpression in the LN229 and U251 potently changed EZH2 expression both in protein and mRNA levels (Fig. 2d and Fig. S2f). Through analysis of ChIP-seq data from GEO (GSE55105) and motif prediction from ALGGEN, we identified that p65 could potentially bind to several regions – 583bp/-574bp, -488bp/-479bp and + 50bp/+59bp in the human EZH2 promoter (Fig. S2g, h). To determine the region(s) of EZH2 promoter involved in NF- κ B regulation, we performed transient transfection with a series of truncated and mutated EZH2 promoter/luciferase reporter constructs in LN229 and U251 cells (Fig. 2e-h). The results revealed that p65 regulates the EZH2 promoter via the – 488bp/-479bp region in GBM cells. ChIP-qPCR was used to examine the endogenous occupancy of this site by p65 in LN229 and U251 cells and demonstrated enrichment of p65 specifically on this region of the EZH2 promoter (Fig. 2i), confirming NF- κ B regulates EZH2 expression by transcription via its promoter. It has been proposed that EZH2 interacts with NF- κ B to promote its activation[30]. However, our co-IP assays did not detect the interaction between EZH2 and p65 in GBM cells (Fig. S2e).

To establish the prominence of EZH2 in mediating the NF- κ B-induced H3K27 trimethylation, we used LPS to activate NF- κ B in WT, EZH2 KO and EZH2 KO + OE LN229 and U251 cells. The results indicate that EZH2 is crucial in inducing H3K27 trimethylation via NF- κ B in GBM cells (Fig. 2j).

NF- κ B inhibition triggers profound epigenetic reprogramming in GBM

In GBM, NF- κ B activates global methylation of H3K27 through EZH2. Recent research has also established that chronic inflammation can lead to epigenetic reprogramming in macrophages[31]. However, whether NF- κ B regulates the redistribution of H3K27me3 remains unclarified. Thus, we performed ChIP-seq to uncover the mechanisms involved. Existing studies have shown that EZH2 is a classic methyltransferase that regulates H3K27me3. In concordance, we analysed the enrichment regions of H3K27me3 and EZH2 in the untreated controls and found that EZH2 and H3K27me3 had a total of overlapping 49,930 peaks (Fig. 3a). The statistical analysis indicated a significant and robust correlation between EZH2 binding and H3K27me3 (Fig. S3a).

Next, we explored further the influence of NF- κ B on the distribution of H3K27me3. Through differential analysis, we selected peaks with a $\log_{10}$ likely-hood ratio > 3 to generate heatmaps. The experimental results showed that in the CAPE group, 733 peaks were increased and 894 peaks reduced, while in the KO group, 672 peaks were increased and 6412 peaks reduced, indicating that inhibition of NF- κ B can mediate epigenetic reprogramming through H3K27me3 (Fig. 3b, c). To uncover the function of H3K27me3 redistribution on GBM malignant progression, we performed GO analysis on the H3K27me3 redistributed genes and found that altered genes expression plays a critical role in promoting tumorigenesis of GBM (Fig. S3d, e).

Based on the functions of genes silenced through H3K27me3[32], we decided to focus on the genes enriched in the promoter regions (Fig. 3d and Fig. S3f). There were 386 differentially enriched promoters in the inhibitor group, while the KO group had 822 differential regions. To investigate which genes are both varyingly enriched and expressed, we compared the 822 differentially enriched genes screened by

ChIP-seq with the differentially expressed genes filtered by RNA-seq. The analysis showed that 133 genes with reduced enrichment had their RNA expression up-regulated, and six genes with increased enrichment had their RNA expression down-regulated upon p65 KO (Fig. S3g). We then selected the tumour suppressor genes GPC5 and CNTNAP2 and the oncogenes C3 and LPL from the down- and up-regulated expression groups respectively for further validation (Fig. 3e, f). The subsequent RT-qPCR analysis confirmed the ChIP-seq and RNA-seq results (Fig. 3g, h).

NF- κ B signalling promotes the proliferation and migration of GBM is partly dependent on EZH2

Both NF- κ B and EZH2 have previously been reported to be crucial for the malignant progression of GBM[14, 33]. We have also demonstrated that NF- κ B induces epigenetic reprogramming through EZH2. However, whether NF- κ B regulates the malignant progression of GBM through EZH2 is still unclear. To test this conjecture, we first used CRISPR/Cas9 to genetically delete EZH2 and p65 in GBM cells (Fig. S5f-j). To identify the roles of NF- κ B and EZH2 in GBM gene expression, we compared the RNA-seq results of the p65 and EZH2 KO GBM cells with their respective WT control cells. The volcano plot illustrated that 2043 differentially expressed genes upon p65 KO and 1961 upon EZH2 KO (Fig. 4a). We performed GO analysis of the differential genes, and the results suggested that both p65 and EZH2 regulate the malignant progression of GBM cells by affecting their proliferation, apoptosis, cell cycle, and migration (Fig. S4a). Next, we tested if the tumorigenic functions of NF- κ B are dependent on EZH2. To this end, we analysed the 794 p65-controlled genes whose expression is also regulated by EZH2 (708 upregulated and 88 downregulated genes, Fig. S4b), and the results showed that these genes considerably regulate GBM proliferation and migration (Fig. S4c). Finally, we selected a number of core p65-regulated genes related to proliferation and migration to verify their regulation by EZH2 using RT-qPCR, suggesting that the expression levels of these p65-regulated genes are controlled by EZH2 (Fig. 4b, c).

Next, we performed CCK-8, colony formation, and transwell assays in LN229 and U251 cell lines with p65 knockout (KO), p65 KO with p65 ectopic overexpression (OE) and p65 KO with EZH2 ectopic overexpression, respectively (Fig. 4d-f and Fig. S4 d-f). It was found that ectopic overexpression of both p65 and EZH2 could rescue the deletion of p65 in p65 KO cells, suggesting NF- κ B targets EZH2 to promote GBM cell proliferation and migration. Conversely, p65 could only partially rescue the effects of EZH2 KO, suggesting that EZH2 functions downstream of NF- κ B.

To further confirm that EZH2 plays a pivotal role in NF- κ B-mediated proliferation and migration, we used LPS to activate NF- κ B in LN229 and U251 cells with EZH2 KO, EZH2 KO and EZH2 ectopic expression. The GBM cells were examined by CCK-8, colony formation, and transwell assays. Our results indicated that LPS, a potent activator of NF- κ B, can significantly enhance proliferation and migration in control GBM cells but not in EZH2-KO cells. However, this loss in oncogenic phenotypes caused by EZH2-KO could be reversed through re-expression of EZH2 (Fig. 4g-i and Fig. S4g-i). Together, our findings suggest that NF- κ B promotes GBM proliferation and migration via EZH2 dependent and independent pathways.

NF- κ B signalling promoting the apoptosis and cell cycle of GBM is mostly independent of EZH2

Next, we pursued the EZH2-independent NF- κ B-regulated GBM oncogenic pathways. To this end, we performed GO analysis on 1249 genes regulated only by p65 and 1167 genes controlled only by EZH2, and found that NF- κ B regulates the cell cycle and apoptosis processes independent of EZH2 (Fig. S5a). Then, we selected some representative cell cycle and apoptotic genes for verification with RT-qPCR, which confirmed our findings (Fig. 5a, b). Next, we used the above groups of selected genes to perform cell cycle and apoptosis assays. The results verified that NF- κ B controls the cell cycle and apoptosis processes mostly independent of EZH2 (Fig. 5c-f and Fig. 5 Sb-e).

GBM can be molecularly stratified for risk by NF- κ B and EZH2

Both NF- κ B and EZH2 contribute to the malignant progression of GBM[14, 34], and we have demonstrated that the two oncogenes display functional interactions in GBM. Initial investigations have shown that the mRNA level of EZH2 or p65 is relative to poor survival in GBM patients, which we confirmed in the CGGA database (Fig. S6a, b). However, the significance of profiling both NF- κ B and EZH2 expression in combination has hitherto not been explored. To better uncover the relationship between EZH2 and p65 in the progression of human glioma, we further examined EZH2 and p65 expression in human glioma samples (n = 180) by immunohistochemical (IHC) staining (Fig. 6a, b). Pearson correlation analysis indicated that EZH2 and p65 expression levels were positively correlated (Fig. S6c).

Next, we categorised the tumours (n = 173) (Supplementary Table 1) into three EZH2/p65 expression groups: low (with low p65 and EZH2 expression; n = 70), intermediate (with high levels of either p65 or EZH2; n = 72), and high-(with high levels of either p65 or EZH2; n = 31). The statistical analysis illustrated that the EZH2/p65 axis was dramatically relative to age, glioma grades and EGFR expression, suggesting that high levels of both p65 and EZH2 expression are correlated to a higher risk of GBM development and progression (Supplementary Table 2). In agreement, Kaplan-Meier analysis also indicated that high EZH2/p65 expression is associated with a poorer prognosis (Fig. 6c-e). Statistic of 5-OS and 5-DFS on different clinicopathological factors by Kaplan-Meier shown the details (Fig. S6d-k and Supplementary Table 3).

Synthetic lethality induced by inhibition of EZH2 and NF- κ B in GBM

Recent research has also demonstrated that inhibiting EZH2 methyltransferase activity in cancer cells is synthetic lethal with deficiency of the chromatin remodeling gene ARID1A[35]. Our results thus far identified that the development of GBM is regulated by NF- κ B through EZH2-dependent and independent

pathway and led us to hypothesize that targeting of NF- κ B can enhance the anti-cancer effects of EZH2 inhibition in GBM.

Firstly, we estimated five small molecule EZH2 inhibitors for their efficacy in restricting the growth of WT and p65 KO GBM cells using the previously established inhibitor IC₅₀ values (Fig. 7a). The results indicated that all five small molecule inhibitors significantly and specifically suppressed the proliferation of p65 KO cells contrasted to WT control cells (Fig. 7b), with EPZ-6438 displaying the highest selective efficiencies against p65 KO cells. We further demonstrated that p65 KO or pharmacological inhibition of EZH2 alone was insufficient to limit LN229 and U251 cell proliferation in both short-term CCK-8 and long-term colony formation assays *in vitro*. Results also showed that cancer cell proliferation was significantly attenuated when NF- κ B and EZH2 inhibition were combined (Fig. 7c, d). This effect was also confirmed in cell cycle and apoptosis assays (Fig. 7e, f). Concisely, the above outcomes showed that inhibition of both NF- κ B and EZH2 is synthetic lethal in GBM.

Despite being tested in clinical studies, some of the EZH2 inhibitors have been reported to be involved in developing multidrug resistance. However, the anti-proliferative effects of EPZ-6438 have been shown to be significantly enhanced when combined with the chemotherapeutic regime CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), suggesting EZH2 inhibitors have potent anticancer activities when administered with other therapeutics[36, 37]. Our results have shown that NF- κ B depletion sensitizes EZH2 inhibitors to reducing GBM cell viability, an observation that has not been described previously. Given the existence of NF- κ B inhibitors and considering our findings, we speculated that such NF- κ B inhibitors could synergize with EPZ-6438 to reduce the growth of GBM cells.

The proliferation results indicated that the EZH2 inhibitor EPZ-6438 synergised with the NF- κ B inhibitor CAPE in inducing anti-proliferative activities in both LN229 and U251 GBM cell lines. (Fig. 7g and Fig. S7a, b). Consistently, western blot analysis also showed that combining CAPE with EPZ-6438 had a more significant effect on repressing H3K27me₃ than either agent alone in LN229 and U251 cells (Fig. 7h). Similar enhanced anti-proliferative functions were also observed when combining CAPE with EPZ-6438 in colony formation, cell cycle, apoptosis assays (Fig. S7c-e). To corroborate these findings, we evaluated the combinational effects of CAPE and EPZ-6438 in GBM BA1B/c-mouse xenograft models (Fig. 7i and Fig. S7f). Although CAPE or EPZ-6438 alone effectively restricted GBM tumour growth, the combination more effectively blocked tumour progression than the single-agent alone *in vivo* (Fig. 7j, k). Lastly, we used IHC to examine the expression levels of Ki67 and H3K27me₃ and HE staining to detect the progression of the tumours (Fig. 7l). We found that simultaneous inhibition of CAPE and EPZ-6438 suppresses GBM growth more effectively than either agent alone *in vivo*.

Together, these data demonstrated that NF- κ B inhibitor CAPE synergises with the EZH2 inhibitor EPZ-6438 to suppress the development of GBM both *in vitro* and *in vivo*.

Discussion

GBM is still an incurable disease and lacks any appropriate targets for effective treatment in the clinic. The inflammatory microenvironment is an essential component of the vast majority of tumours through enhancing their malignant progression[7, 8]. The blood-brain barrier is destroyed by GBM, causing chronic neuroinflammation that is a cardinal feature of GBM biology[3]. Chronic inflammation is relative to poor outcomes and reduced responsiveness to treatment in tumour (including GBM) patients[7, 38]. At the same time, epigenetic modifications have also been described to be essential in tumorigenesis, and are therefore exploited as therapeutic targets for treating cancer[39]. Recent evidence indicates inflammation is associated with epigenetic modifications, which is supported by the observation in macrophages[31]. However, their functional connection and combinatory impact on cancer, especially on GBM, remain unclear. Therefore, exploring the potential link of inflammation to epigenetic alterations can unveil novel and effective strategies for the stratification and treatment of GBM.

NF- κ B serves as a significant link between chronic inflammation and cancer[11]. Like many other malignancies, GBM has been demonstrated to possess high levels of NF κ B activity[27]. Histone lysine methylation is one of the most important epigenetic modifications, playing a critical role in health and disease[18]. Here, we found that NF- κ B activation specifically dictates H3K27 methylation via upregulating transcription of EZH2 which is also critical for promoting GBM malignant progression, thus revealing the crosstalk between inflammation and epigenetics. To this end, we firstly detected the global expression of H3K4me3, H3K9me3, H3K27me3, and H3K36me3. We found that NF- κ B only modulates the methylation levels of H3K27, but not H3K4, H3K9 and H3K36 in GBM cells. To further identify histone enzymes involved in the methylation of H3K27, we screened a number of methyltransferases and demethylases in GBM cells and identified EZH2 as the principal methyltransferase specifically responsible for H3K27 trimethylation. Mechanistically, we confirmed that the canonical NF κ B signalling mediated by p65/p50 directly regulates the transcription of EZH2, resulting in a global change of expression and distribution of H3K27me3. In agreement, NF- κ B2, the regulator of the non-canonical NF κ B signalling, has previously been found to activate EZH2 to promote senescence bypass in melanoma[40]. In GBM, however, it is the canonical NF κ B signalling (rather than the non-canonical) that is constitutively activated to drive EZH2 expression and tumour progression. Meanwhile, our findings is opposed to the likelihood that NF κ B physically binds with EZH2 to regulate the activity of the latter molecule as reported by others[30]. Taken together, we identify a key axis from the canonical NF- κ B pathway to the EZH2 signaling, linking chronic inflammation and epigenetic reprogramming and promoting the malignant progression of GBM.

Based on genetic and epigenetic features, WHO has changed the CNS Tumour Classification to a molecular categorization such as IDH-wildtype and IDH-mutant glioblastoma, H3K27M-mutant diffuse midline glioma, and p65 fusion-positive ependymoma, etc^[41] [42, 43]. Meanwhile, these aberrant molecules also represent attractive therapeutic targets for drug development. Thus far, GBM is still a fatal disease without efficient therapeutic treatment. Consequently, it becomes particularly urgent to search for novel molecular biomarkers to predict the prognosis and to make individualized regimens. EZH2 or NF- κ B over-activation has previously been determined relative to the development of GBM[14, 33]. The prognostic

significance of their combination has hitherto been uncovered. It is the first time that we verified co-activation of NF- κ B and EZH2 confers the poorest clinic outcome and the risk and prognosis of GBM can be reliably stratified according to the expression of EZH2 and p65 [low-risk: low p65 and EZH2 expression; intermediate-risk: high either p65 or EZH2 expression; and high-risk: high p65 and EZH2 expression; DFS and OS ($p < 0.0001$)]. This novel strategy will aid the diagnosis and clinical management of patients with GBM. Moreover, these findings prove further clinical evidence for the idea that EZH2 and NF- κ B combine to promote the development and progression of GBM.

EZH2 is a crucial subunit of the PRC2 and catalyzes H3K27me_{2/3}, which are linked to transcriptional silence[23, 44]. In multiple cancers, EZH2 is frequently over-activated to promote tumorigenesis, making it a promising drug target for cancer treatment[45]. Whereas the efficacy of EZH2 inhibitors (EZH2i) as single agents has not lived up to their earlier high expectations in the clinic. Accordingly, EZH2i treatment alone is ineffective or causes multidrug resistance in some EZH2-overexpressing solid tumours. Nevertheless, further preclinical studies also suggest that combining EZH2i with other therapies has a synergistic anti-cancer impact, revealing cancer cells can be sensitised to EZH2i in the presence of an additional perturbation[46].

Being an essential transcription factor, NF- κ B is implicated in regulating hundreds of genes in various types of biological processes and diseases[47]. As mentioned above, NF- κ B is a lynchpin linking chronic inflammation and cancer, and it is frequently activated in multiple cancers. Just like EZH2, NF- κ B has long been regarded as a potential therapeutic target of cancer. However, inhibition of NF- κ B alone will not affect most solid tumours.[48] Paradoxically, NF- κ B inhibition alone may promote tumour progression due to the pro-apoptotic potential of NF- κ B[49]. In past decades, no any encouraging results have been acquired in all clinical trials except that various inhibitors, including natural compounds like CAPE are guaranteed in safety and availability[50]. Therefore, it is still a great challenge to targeting of NF- κ B for cancer treatment. It is notable that NF- κ B may regulate epigenetic reprogramming and biological processes via EZH2-dependent and EZH2-independent manner, suggesting that NF- κ B can potentially cooperate with EZH2 in more than one way to impact tumorigenesis. In this study, cancer cells can be induced to a synthetic lethality by EZH2i upon genetic ablation of NF- κ B, indicating that redundant survival pathway(s)/mechanism(s) of EZH2 can compensate for the loss of NF- κ B activity. EPZ-6438 is one of the most effective EZH2i and is performed Phase I clinical trial in several types of cancer patients. Our study demonstrated that combined targeting of NF- κ B and EZH2 with CAPE and EPZ-6438 respectively have synergistic suppression of cancer *in vitro* and *in vivo* and therefore provides information for devising strategies of synthetic lethality for the treatment of GBM. However, whether this pharmacological effect also holds in other cancers requires further investigation.

The exact underlying mechanistic basis for the cooperation between the NF- κ B and EZH2 inhibitors remains unclear and warrants further investigation. Possibly, it is as a result of NF- κ B could induce EZH2 independent and dependent epigenetic reprogramming via H3K27me₃. In concordance with this idea, a recent study has shown that genetic ablation/deletion or pharmacological inhibition of EZH2 triggered feedback activation of NF- κ B via the EZH2-SOX9-TNFRSF11A signalling axis in prostate cancer cells.

Mechanistically, EZH2 represses SOX9 gene expression and inactivation causes derepression of SOX9, a transcriptional regulator of TNFRSF11A, which in turn is a receptor activator of NF- κ B[51]. In addition, EZH2 has also been demonstrated to bind to NKILA and disrupt the reciprocal negative feedback inhibition between NKILA and NF- κ B[52].

Conclusions

Both chronic inflammation and epigenetic reprogramming are hallmarks of cancer. Here, we established their functional cooperation in the context of GBM. In further agreement, we also found that co-activation of the canonical NF- κ B pathway and EZH2 signaling confers the poorest clinical outcome, and the expression of EZH2 and p65 which is the core subunit of NF- κ B in combination can be used to stratify the risk and prognosis in GBM patients reliably. Most importantly, we demonstrated the synthetic lethality between inhibition of NF- κ B and EZH2. Being predominantly dysregulated in cancer, NF- κ B and EZH2 have long been regarded as key targets for cancer treatment. Although great efforts have been made in past decades, targeting NF- κ B or EZH2 alone has never made any clinical progress except that several inhibitors are guaranteed in safety and availability. Now, our work highlights that combined targeting of the NF- κ B and EZH2 pathways by inhibitors guaranteed in safety and availability probably are potent in the treatment of GBM patients.

Abbreviations

GBM
Glioblastoma multiforme
NF- κ B
Nuclear factor kappa B
EZH2
Enhancer of zeste 2
SPF
Specific pathogen free
CAPE
Caffeic acid phenethyl ester
ATCC
American Type Culture Collection
STR
Short tandem repeat
GO
gene ontology

Declarations

Acknowledgement

We would like to thank Dr. Wei Cheng (ICSC Core Facility, Dalian Medical University) for her material and technical support.

Funding

This work is supported by grants from National Natural Science Foundation of China (Nos. 81873441); Science and Technology Innovation Leading Talent Program of Liaoning Province (XLYC1902036); Basic Research on the Application of Dalian Innovation Fund (2019J12SN56); Key R & D projects in Liaoning Province (2019JH8/10300027); Key Project of the Educational Department of Liaoning Province (LZ2020003).

Author's contributions

Conception and design by KL, WG, NC, HW, JY, DJ and BJ; development of methodology by KL, WG, NC; acquisition of data by KL, WG, NC; analysis and interpretation of data (for example, statistical analysis, flow cytometry interpretation) by KL, WG, NC, HW, RW, JM, CM; writing, review and revision of the manuscript by KL, WG, NC, LE, SL, NK, FX, YH, ZW, QG, SY, LG, DJ and BJ; administrative, technical or material support: WC, DJ and BJ; study supervision: HW, JY, DJ and BJ. The author (s) read and approved the final manuscript.

Ethics approval and consent to participate

All primary glioma tissue samples and matching clinical data were obtained from Xinchao (Shanghai). Written informed consent was obtained from all adult patients.

Consent for publication

We have received consents from individual patients who have participated in this study. The consent forms will be provided upon request.

Competing of interests

The authors declare no competing interests.

Author details

¹ Institute of Cancer Stem Cell; Liaoning Key Laboratory of Nucleic Acid Biology, Dalian Medical University, Dalian 116044, Liaoning, China. ² Department of Hematology; Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine; Liaoning Medical Center for Hematopoietic Stem Cell Transplantation; Dalian Key Laboratory of Hematology; Diamond Bay Institute of Hematology, Second Hospital of Dalian Medical University, Dalian 116044, China. ³ Boao International Hospital, Shanghai University of Traditional Chinese Medicine, Qionghai 571734, Hainan, China. ⁴ State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-

References

1. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, et al: The epidemiology of glioma in adults: a "state of the science" review. *Neuro Oncol* 2014, 16:896–913.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *The Lancet Oncology* 2009, 10:459–466.
3. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A, Saberi H, Ardakan MMM, Ai A, Soleimannejad M, Ai J: Anti-inflammatory Effects of Atorvastatin in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. *Mol Neurobiol* 2018, 55:2102–2110.
4. Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, Lee Y, Kim SH, Lee SY, Seo S, et al: TP53 gain-of-function mutation promotes inflammation in glioblastoma. *Cell Death Differ* 2019, 26:409–425.
5. Roesler R, Dini SA, Isolan GR: Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches. *Clin Exp Immunol* 2021, 206:314–324.
6. Alghamri MS, McClellan BL, Hartlage MS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, et al: Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. *Front Pharmacol* 2021, 12:680021.
7. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. *Nature* 2008, 454:436–444.
8. Quail DF, Joyce JA: The Microenvironmental Landscape of Brain Tumors. *Cancer Cell* 2017, 31:326–341.
9. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. *Cell* 2011, 144:646–674.
10. Hoesel B, Schmid JA: The complexity of NF-kappaB signaling in inflammation and cancer. *Mol Cancer* 2013, 12:86.
11. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005, 5:749–759.
12. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* 2004, 431:461–466.
13. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 2004, 118:285–296.

14. Cahill KE, Morshed RA, Yamini B: Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy. *Neuro Oncol* 2016, 18:329–339.
15. Gray GK, McFarland BC, Nozell SE, Benveniste EN: NF-kappaB and STAT3 in glioblastoma: therapeutic targets coming of age. *Expert Rev Neurother* 2014, 14:1293–1306.
16. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet* 2007, 8:286–298.
17. Dawson MA: The cancer epigenome: Concepts, challenges, and therapeutic opportunities. *Science* 2017, 355:1147–1152.
18. Husmann D, Gozani O: Histone lysine methyltransferases in biology and disease. *Nat Struct Mol Biol* 2019, 26:880–889.
19. Black JC, Van Rechem C, Whetstone JR: Histone lysine methylation dynamics: establishment, regulation, and biological impact. *Mol Cell* 2012, 48:491–507.
20. Wilson CL, Mann DA, Borthwick LA: Epigenetic reprogramming in liver fibrosis and cancer. *Adv Drug Deliv Rev* 2017, 121:124–132.
21. Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. *Cell* 2012, 150:12–27.
22. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, et al: Polycomb complexes repress developmental regulators in murine embryonic stem cells. *Nature* 2006, 441:349–353.
23. Margueron R, Reinberg D: The Polycomb complex PRC2 and its mark in life. *Nature* 2011, 469:343–349.
24. Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A, Shah AH, Wahlestedt C, Ayad NG: Epigenetic pathways and glioblastoma treatment. *Epigenetics* 2013, 8:785–795.
25. Hanahan D: Hallmarks of Cancer: New Dimensions. *Cancer Discov* 2022, 12:31–46.
26. Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-kappaB as the matchmaker. *Nat Immunol* 2011, 12:715–723.
27. Atkinson GP, Nozell SE, Harrison DK, Stonecypher MS, Chen D, Benveniste EN: The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. *Oncogene* 2009, 28:3735–3745.
28. Chi P, Allis CD, Wang GG: Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. *Nat Rev Cancer* 2010, 10:457–469.
29. Taniguchi K, Karin M: NF-kappaB, inflammation, immunity and cancer: coming of age. *Nat Rev Immunol* 2018, 18:309–324.
30. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, Liou YC, Yu Q: Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. *Mol Cell* 2011, 43:798–810.
31. Glass CK, Natoli G: Molecular control of activation and priming in macrophages. *Nat Immunol* 2016, 17:26–33.

32. Schuettengruber B, Bourbon HM, Di Croce L, Cavalli G: Genome Regulation by Polycomb and Trithorax: 70 Years and Counting. *Cell* 2017, 171:34–57.
33. Zhai X, Li LS, Zhou YD, Ji WY, Chen H, Xiao H, Liang P: EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability. *Eur J Pharmacol* 2021, 904:174177.
34. Yu T, Wang Y, Hu Q, Wu W, Wu Y, Wei W, Han D, You Y, Lin N, Liu N: The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. *Oncotarget* 2017, 8:98348–98359.
35. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih le M, Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat Med* 2015, 21:231–238.
36. Knutson SK, Warholc NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, Porter-Scott M, Smith JJ, Moyer MP, et al: Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. *PLoS One* 2014, 9:e111840.
37. Lee DH, Ryu HW, Won HR, Kwon SH: Advances in epigenetic glioblastoma therapy. *Oncotarget* 2017, 8:18577–18589.
38. Sciume G, Santoni A, Bernardini G: Chemokines and glioma: invasion and more. *J Neuroimmunol* 2010, 224:8–12.
39. Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, Ashraf GM: Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. *Semin Cancer Biol* 2020.
40. De Donatis GM, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, et al: NF- κ B2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. *Oncogene* 2016, 35:2735–2745.
41. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 2016, 131:803–820.
42. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008, 321:1807–1812.
43. Geraldo LHM, Garcia C, da Fonseca ACC, Dubois LGF, de Sampaio ESTCL, Matias D, de Camargo Magalhaes ES, do Amaral RF, da Rosa BG, Grimaldi I, et al: Glioblastoma Therapy in the Age of Molecular Medicine. *Trends Cancer* 2019, 5:46–65.
44. Laugesen A, Hojfeldt JW, Helin K: Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation. *Mol Cell* 2019, 74:8–18.
45. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* 2012, 492:108–112.

46. Bates SE: Epigenetic Therapies for Cancer. *N Engl J Med* 2020, 383:650–663.
47. Zhang Q, Lenardo MJ, Baltimore D: 30 Years of NF-kappaB: A Blossoming of Relevance to Human Pathobiology. *Cell* 2017, 168:37–57.
48. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. *J Clin Invest* 2001, 107:241–246.
49. Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-kappaB in p53-mediated programmed cell death. *Nature* 2000, 404:892–897.
50. Natarajan K, Singh S, Burke TR, Jr., Grunberger D, Aggarwal BB: Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. *Proc Natl Acad Sci U S A* 1996, 93:9090–9095.
51. Jin M, Duan J, Liu W, Ji J, Liu B, Zhang M: Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. *Cancer Cell Int* 2021, 21:191.
52. Duan S, Chan WK, Oman A, Basile DP, Alvira CM, Buxton ILO, Iosef C: NF-kappaB/NKILA signaling modulates the anti-cancerous effects of EZH2 inhibition. *J Cell Mol Med* 2019, 23:6182–6192.

Figures

Figure 1

Canonical NF- κ B signalling specifically activates global methylation of H3K27 in GBM. **a** NF- κ B activation status in GBM samples. Results showed by western blotting. **b** Protein expression of p65 and p-p65 in five general GBM cell lines. Results showed by western blotting. **c** LN229 and U251 cells were assayed by Immunofluorescence. **d** The LN229 and U251 cells were cultured in 5 μ M BAY11 or 3 μ M CAPE. Levels of histone lysine methylation were detected by western blotting. **e** LN229 and U251 cells were transfected with si NC oligos or si p65 oligos. Levels of histone lysine methylation were detected by western blotting. **f** Rescue experiment performed in LN229 and U251 cells. Results showed by western blotting. **g, h** The expression levels of H3K27me1/2/3 upon knockdown p65 or NF- κ B inhibitors in LN229 and U251 cells. Results showed by western blotting. Values are expressed as the means $\pm$ SD from three experiments

Figure 2

NF- κ B selectively triggers the expression of EZH2 to promote H3K27 methylation in GBM. **a** Relative mRNA expression of H3K27 specific methyltransferase and demethylase in LN229 and U251 cells were measured by RT-qPCR. **b** Inhibiting the activation of the NF- κ B pathway by treating with 5 μ M BAY11 or 3 μ M CAPE and then detecting the protein expression levels of EZH2 in LN229 and U251 cells. **c** EZH2 protein levels determined by western blot in LN229 cell lines, which was transfected with siRNAs directed

against the major components of the NF- κ B canonical and non-canonical pathway for 48h. **d** Expression levels of EZH2 in LN229 and U251 cells after knockdown of p65. **e,f** Luciferase activities after truncation fragments in LN229 and U251 cells. **g, h** Luciferase activities after mutation of -488 bp ~ -479 bp fragments in LN229 and U251 cells. **i** ChIP-qPCR of the EZH2 promoter, immunoprecipitated with antibodies against p65 in LN229 cells. **j** Western blot shows the level of EZH2 and H3K27me3 in the LN229 and U251 cell lines of EZH2 KO and EZH2 KO+OE after activating the NF- κ B pathway by LPS compared to the control group. Values are expressed as the means $\pm$ SD from three experiments, and the asterisk indicates the statistical significance compared to the controls (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, ****, $p < 0.0001$).

Figure 3

NF- κ B inhibition triggers profound epigenetic reprogramming in GBM. **a** Venn diagram shows the overlapping between EZH2 and H3k27me3 enrichment in control. **b-c** Heatmap representation of regions with either loss or gain ($\log_{10}$ likely-hood ratio > 3) of H3K27me3 in p65 KO LN229 cells compared with WT. The $\log_2(\text{IP}/\text{Input})$ signal is plotted for each replicate, centered on the differential peak ± 5 kb. The same assay was performed in LN229 treated with DMSO or CAPE. **d** The pie chart shows the percentage

of each type of differential enrichment region in WT and p53 KO LN229 cells. **e-f** IGV browser views for H3K27me3 ChIP-seq libraries at four representative loci. The y axis corresponds to the ChIP-seq signal intensity. Gene representation at each locus is shown at the bottom. **g-h** RT-qPCR assay detected the differential mRNA levels analyzed by RNA-seq and the differential peaks analyzed by ChIP-seq. Values are expressed as the means $\pm$ SD from three experiments, and the asterisk indicates the statistical significance compared to the controls (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, ****, $p < 0.0001$).

Figure 4

NF- κ B signalling promotes the proliferation and migration of GBM is partly dependent on EZH2. **a** Volcano plots illustrate differentially regulated genes expression between WT and p65/EZH2 KO LN229 cells identified by RNA-seq. Values are presented as the $\log_2$ of foldchange. **b** Heatmaps of candidate genes relative to proliferation and migration were both regulated by NF- κ B and EZH2. **c** RT-qPCR detects the mRNA levels of candidate genes relative to proliferation and migration in WT and EZH2 KO LN229 cells treated with PBS or LPS. **d-f** CCK-8, colony formation, transwell assays in the LN229 cell line of WT, p65 KO, p65 KO with p65 ectopic overexpression and p65 KO with EZH2 ectopic overexpression groups or WT, EZH2 KO, EZH2 KO with EZH2 ectopic overexpression and EZH2 KO with p65 ectopic overexpression groups. **g-i** CCK-8, colony formation, transwell assays in WT, EZH2 KO and EZH2 KO with EZH2 ectopic overexpression LN229 cells treated with PBS or LPS. Values are expressed as the means $\pm$ SD from three experiments, and the asterisk indicates the statistical significance compared to the controls (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, ****, $p < 0.0001$).

Figure 5

NF- κ B signalling promoting the apoptosis and cell cycle of GBM is mostly independent of EZH2. **a** Heatmap of candidate genes was only regulated by NF- κ B. **b** RT-qPCR detects the mRNA levels of genes relative to apoptosis and cell cycle in WT and EZH2 KO LN229 cells treated with PBS or LPS. **c, d** Cell cycle and apoptosis assays in the LN229 cell line of WT, p65 KO, p65 KO with p65 ectopic overexpression and p65 KO with EZH2 ectopic overexpression groups or WT, EZH2 KO, EZH2 KO with EZH2 ectopic overexpression and EZH2 KO with p65 ectopic overexpression groups. **e, f** Cell cycle and apoptosis assays in WT, EZH2 KO and EZH2 KO with EZH2 ectopic overexpression LN229 cells treated with PBS or

LPS. Values are expressed as the means±SD from three experiments, and the asterisk indicates the statistical significance compared to the controls (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, ****, $p < 0.0001$).

Figure 6

GBM can be molecularly stratified for risk using NF- κ B and EZH2. **a** High and low expression of EZH2 and p65 protein in GBM were detected by immunohistochemical staining Tissue Microarray(n=180). **b** Tissue Microarray EZH2 and p65 staining. Representative 40X views of tumors showing for the relative between EZH2 and p65. **c,d** The Kaplan–Meier survival curves of three risk groups. **e** Summary of clinical data and molecular characteristics of low-, intermediate and high-risk groups. GBM were divided into three groups

according to molecular markers. Values were expressed as the means±SD from three experiments, and the asterisk indicates the statistical significance compared to the controls (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, ****, $p < 0.0001$).

Figure 7

Synthetic lethality induced by inhibition of EZH2 and NF- κ B in GBM. **a** WT and p65 KO LN229 cells were treated with DMSO or EZH2 inhibitors, including EPZ-6438, GSK126, EPZ005687, GSK343, GSK503. Cell viability was measured at different time points after treatment using CCK8 assays. **b** The x-axis indicates the 4500D value formed by treated WT LN229 cells, and the y-axis shows the 4500D value by p65 KO LN229 cells treated with the same small molecule. **c** The EZH2 small molecule inhibitor EPZ-6438 sensitizes p65-KO LN229 and U251 cells detected by CCK8 assay. **d~f** Colony formation, cell cycle and apoptosis assay were performed in the sample groups. **g** LN229 and U251 cell lines were treated with increasing doses of EPZ-6438 combined with CAPE for 24 hours, and proliferation was monitored by CCK8-kit. LOEWE scores and heatmaps were calculated by Combenefit. **h** LN229 and U251 cells were harvested from drug-therapeutic cells at the end of the treatment (24h), then immunoblotted as indicated. **i** Subcutaneously implanted mice were treated with EPZ-6438, CAPE or combination. Images of representative tumors for every group at day 28. **j, k** Changes of tumor volume(j) and tumor weight(k) treated with CAPE, EPZ-2438 or combination groups during day 28. **l** IHC staining using Hematoxylin and eosin (H&E) for Ki67 and H3K27me3. Values are expressed as the means $\pm$ SD from three experiments, and the asterisk indicates the statistical significance compared to the controls (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, ****, $p < 0.0001$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure1.pdf](#)
- [SupplementaryFigure2.pdf](#)
- [SupplementaryFigure3.pdf](#)
- [SupplementaryFigure4.pdf](#)
- [SupplementaryFigure5.pdf](#)
- [SupplementaryFigure6.pdf](#)
- [SupplementaryFigure7.pdf](#)
- [SupplementaryFigure8.pdf](#)
- [SupplementaryTable1Clinicopathologiccharacteristics1.docx](#)
- [SupplementaryTable2Clinicopathologiccharacteristics2.docx](#)
- [SupplementaryTable3Clinicopathologiccharacteristics3.docx](#)
- [SupplementaryTable4RTPCRandqPCRprimers.docx](#)
- [SupplementaryTable5plasmidprimers.docx](#)
- [Supplementarylegends20220225.docx](#)